共 50 条
- [1] Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantationBlood Cancer Journal, 11Benjamin A. DermanAndrew T. StefkaKen JiangAmanda McIverTadeusz KubickiJagoda K. JasielecAndrzej J. Jakubowiak
- [2] Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone InductionBLOOD, 2014, 124 (21)Weltz, Jonathan I.Landau, HeatherLendvai, NikolettaChung, David J.Lesokhin, Alexander M.Devlin, Sean M.Riedel, ElynWoo, Kaitlin M.Stellman, AmandaChimento, DanielleKewalramani, TarunLandgren, OlaGiralt, SergioComenzo, Raymond L.Hassoun, Hani
- [3] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)BLOOD, 2023, 142Derman, Benjamin A.Cooperrider, Jennifer H.Rosenblatt, JacalynAvigan, DavidRampurwala, Murtuza M.Major, AjayKarrison, TheodoreJiang, KenKubicki, TadeuszJakubowiak, Andrzej J.
- [4] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Zimmerman, Todd M.Griffith, Kent A.Jasielec, JagodaRosenbaum, Cara AnnMcDonnell, KathrynWaite-Marin, JessicaBerdeja, Jesus G.Raje, Noopur S.Reece, Donna EllenVij, RaviAlonge, MattinaRosebeck, ShaunGurbuxani, SandeepFaham, MalekKong, Katherine A.Levy, JoanJakubowiak, Andrzej J.
- [5] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialLANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720Gay, FrancescaMusto, PellegrinoRota-Scalabrini, DeliaBertamini, LucaBelotti, AngeloGalli, MonicaOffidani, MassimoZamagni, ElenaLedda, AntonioGrasso, MariellaBallanti, StelvioSpadano, AntonioCea, MichelePatriarca, FrancescaD'Agostino, MattiaCapra, AndreaGiuliani, Nicolade Fabritiis, PaoloAquino, SaraPalmas, AngeloGamberi, BarbaraZambello, RenatoPetrucci, Maria TeresaCorradini, PaoloCavo, MicheleBoccadoro, Mario
- [6] Atlas: a phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S6 - S6Jakubowiak, AndrzejWrobel, TomaszJamroziak, KrzysztofKubicki, TadeuszRobak, PawelCzyz, JaroslawTyczynska, AgataDruzd-Sitek, AgnieszkaGiannopoulos, KrzysztofNowicki, AdamLojko-Dankowska, AnnaMatuszak, MagdalenaGil, LidiaPula, BartoszRybka, JustynaUsnarska-Zubkiewicz, LidiaCzabak, OlgaStefka, AndrewDerman, BenjaminDytfeld, Dominik
- [7] Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomideCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S259 - S260Kubicki, TadeuszDytfeld, DominikWrobel, TomaszJamroziak, KrzysztofRobak, PawelCzyz, JaroslawTyczynska, AgataDruzd-Sitek, AgnieszkaGiannopoulos, KrzysztofNowicki, AdamLojko-Dankowska, AnnaMatuszak, MagdalenaGil, LidiaPula, BartoszRybka, JustynaUsnarska-Zubkiewicz, LidiaCzabak, OlgaStefka, AndrewJiang, KenDerman, BenjaminJakubowiak, Andrzej
- [8] Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)Hayman, SuzanneLaPlant, BetsyBuadi, FrancisAsmus, Erik J.Kapoor, PrashantLacy, MarthaDingli, DavidDispenzieri, AngelaKourelis, TaxiarchisWarsame, RahmaGonsalves, Wilson I.Muchtar, EliMiceli, TeresaHogan, William J.Gertz, MorieKumar, Shaji
- [9] Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2023, 24 (02): : 139 - 150Dytfeld, DominikWrobel, TomaszJamroziak, KrzysztofKubicki, TadeuszRobak, PawelWalter-Croneck, AdamCzyz, JaroslawTyczynska, AgataDruzd-Sitek, AgnieszkaGiannopoulos, KrzysztofNowicki, AdamSzczepaniak, TomaszLojko-Dankowska, AnnaMatuszak, MagdalenaGil, LidiaPula, BartoszRybka, JustynaMajcherek, MaciejUsnarska-Zubkiewicz, LidiaSzukalski, LukaszKonska, AgnieszkaZaucha, Jan MaciejWalewski, JanMikulski, DamianCzabak, OlgaRobak, TadeuszLahoud, Oscar B.Zonder, Jeffrey A.Griffith, KentStefka, AndrewMajor, AjayDerman, Benjamin A.Jakubowiak, Andrzej J.
- [10] COLLECTION AND TRANSPLANTATION OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH LENALIDOMIDEBONE MARROW TRANSPLANTATION, 2014, 49 : S49 - S49Grubovic, R. M.Alavi, A.Schiller, G. J.